Literature DB >> 1642695

Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733).

Y Hidaka1, T Eda, M Yonemoto, T Kamei.   

Abstract

The effect of simvastatin (MK-733), a potent 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on the migration of cultured porcine smooth muscle cells (SMCs) was investigated in modified Boyden chambers. Platelet-derived growth factor (PDGF) stimulated the SMC migration dose dependently. MK-733 inhibited the migration response induced by PDGF with an IC50 value of 2 microM. Supplementation with mevalonate restored the migration response inhibited by MK-733 but the addition of low-density-lipoprotein (LDL) did not change the response. Another HMG-CoA reductase inhibitor, pravastatin (CS-514), also reduced the migration response. However its potency was far less than that of MK-733. MK-733 also inhibited the SMC migration stimulated by fibrinogen. These results suggest that non-sterol metabolite(s) of mevalonate, possibly prenylated proteins, are involved in a migration signaling pathway and that HMG-CoA reductase inhibitors are effective in the prevention of the formation of intimal hyperplasia in atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1642695     DOI: 10.1016/0021-9150(92)90179-k

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  9 in total

1.  Role of statins in cerebral vasospasm.

Authors:  T Sugawara; R Ayer; J H Zhang
Journal:  Acta Neurochir Suppl       Date:  2008

Review 2.  Delayed expression of osteopontin after focal stroke in the rat.

Authors:  X Wang; C Louden; T L Yue; J A Ellison; F C Barone; H A Solleveld; G Z Feuerstein
Journal:  J Neurosci       Date:  1998-03-15       Impact factor: 6.167

Review 3.  Current, new and future treatments in dyslipidaemia and atherosclerosis.

Authors:  P H Chong; B S Bachenheimer
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 4.  [Regulation of endothelial NO production by Rho GTPase].

Authors:  U Laufs; M Endres; J K Liao
Journal:  Med Klin (Munich)       Date:  1999-04-15

5.  Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury.

Authors:  E H Ohlstein; S A Douglas; C P Sung; T L Yue; C Louden; A Arleth; G Poste; R R Ruffolo; G Z Feuerstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

6.  The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.

Authors:  A C Calkin; S Giunti; K J Sheehy; C Chew; V Boolell; Y S Rajaram; M E Cooper; K A Jandeleit-Dahm
Journal:  Diabetologia       Date:  2008-07-02       Impact factor: 10.122

7.  Platelet-derived growth factor differentially regulates the expression and post-translational modification of versican by arterial smooth muscle cells through distinct protein kinase C and extracellular signal-regulated kinase pathways.

Authors:  Luiz E M Cardoso; Peter J Little; Mandy L Ballinger; Christina K Chan; Kathleen R Braun; Susan Potter-Perigo; Karin E Bornfeldt; Michael G Kinsella; Thomas N Wight
Journal:  J Biol Chem       Date:  2009-12-30       Impact factor: 5.157

8.  Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis.

Authors:  S Van Doornum; G McColl; I P Wicks
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

9.  Chronic allograft rejection: A significant hurdle to transplant success.

Authors:  Malgorzata Kloc; Rafik M Ghobrial
Journal:  Burns Trauma       Date:  2014-01-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.